QSQiuying Shi

Qiuying Shi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qiuying Shi has a total of 174 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pitfalls in diagnosis of metatypical adenoid cystic carcinoma

    by Genevieve Parecki, Sintawat Wangsiricharoen, Justin A. Bishop, Qiuying Shi

  • Testing insulin‐like growth factor messenger RNA–binding protein 3 as a surrogate immunohistochemical marker for indeterminate thyroid nodules with THADA fusion in both cytologic and surgical specimens

    by Di Ai, Youjie Zhang, Kartik Viswanathan, Jilun Zhang, Kelly R. Magliocca, Scott Steward‐Tharp, Wen‐Yu Hsiao, Qiuying Shi

    Background: Thyroid adenoma‐associated ( THADA ) gene fusions are recurrent alterations in thyroid nodules that lead to the overexpression of insulin‐like growth factor messenger RNA–binding protein 3 (IMP3). Although IMP3 immunohistochemistry has been studied in thyroid tumors, its utility for detecting THADA fusion–positive thyroid specimens remain unassessed. Methods: The authors evaluated IMP3 expression in cytologic and surgical specimens from 20 indeterminate thyroid nodules. Eleven cases harbored THADA fusions, including THADA::IGF2BP3 ( n = 9) and THADA::TRA2A ( n = 2), whereas nine control cases lacked detectable THADA fusions. Hematoxylin‐and‐eosin staining and immunohistochemistry for IMP3 and NRAS Q61R were performed on available cell blocks and surgical specimens. Staining was scored based on extent and intensity, with a composite score >2 considered positive. Results: All nodules with THADA fusions exhibited strong, diffuse, cytoplasmic IMP3 staining in lesional follicular cells, with no staining in adjacent normal thyroid tissue. All control cases were negative for IMP3. NRAS Q61R immunostaining was negative across all cases. Conclusions: The current findings in a limited cohort demonstrate that IMP3 is a promising surrogate marker for indeterminate thyroid nodules with THADA fusions in both cytologic and surgical specimens. In addition, IMP3 staining may aid in detecting subtle capsular or vascular invasion.


  • Risk stratification of ThyroSeq results in indeterminate thyroid lesions: A single‐institution experience of clinicopathologic correlation with cytologic findings

    by Wen‐Yu Hsiao, Nabil F. Saba, Daniel Lubin, Amy Chen, Qiuying Shi

    Background: ThyroSeq offers the opportunity to stratify the risk of malignancy (ROM) in the characterization of indeterminate thyroid nodules, especially those categorized as atypia of undetermined significance (AUS). However, whether ThyroSeq interpretations correlate with cytologic features, management, and surgical outcome remains unclear.Methods: Thyroid fine‐needle aspiration specimens categorized as AUS and follicular neoplasm (FN) from 2017 to 2021 were identified from a cytology database search. Patient clinical information and ThyroSeq results were collected and correlated with resection diagnosis if available.Results: A total of 520 cases were classified as AUS and 111 cases were classified as FN. Within the AUS lesions, 190 cases (36.5%) were subcategorized as cytologic atypia (III‐C), 109 cases (21.0%) as architectural atypia (III‐A), 138 cases (26.5%) as both cytologic and architectural atypia (III‐CA), and 69 cases (13.0%) as oncocytic cell aspirate (III‐O). Category III‐C showed the highest malignancy rate (16.7%; p = .29), and a higher ThyroSeq‐defined probability of cancer or noninvasive follicular thyroid neoplasms with papillary‐like nuclear features. Notably, within III‐C, intermediate‐risk mutations led to a significantly higher malignancy rate (46.7%; p = .0012). Conversely, III‐A had the lowest malignancy rate (9.7%) but this was significantly increased by concurrent high‐risk mutations (62.5%). BRAFV600E‐like mutations were frequently associated with III‐C and classical papillary thyroid carcinoma in histology. RAS‐like mutations were the most common alterations across all subcategories, and were frequently associated with follicular‐patterned lesions.Conclusions: Atypia subcategories have differential ThyroSeq‐defined ROMs and histologic outcomes. Combining atypia subcategory interpretation, ThyroSeq‐defined ROMs and molecular results aids in optimal clinical management for indeterminate thyroid lesions.


  • ThyroSeq overview on indeterminate thyroid nodules: An institutional experience

    by Sam Sirotnikov, Christopher C. Griffith, Daniel Lubin, Chao Zhang, Nabil F. Saba, Dehong Li, Amanda Kornfield, Amy Chen, Qiuying Shi

    Background: Molecular triage of indeterminate thyroid aspirates offers the opportunity to stratify the risk of malignancy (ROM) more accurately. Here we examine our experience with ThyroSeq v3 testing.Methods: We analyzed 276 of 658 (42%) fine needle aspiration samples classified as indeterminate thyroid nodules using ThyroSeq v3 (Sept 2017–Dec 2019). The test provides a ROM and detects specific mutations. Surgical diagnoses were reviewed.Results: Of 276 ThyroSeq‐tested cases, 42% (n = 116) harbored genetic alterations, whereas 64% (n = 74) had surgical follow‐up. Notably, 79% cases within intermediate to higher risk mutations were highly associated with surgical intervention, resulting in a 77.5% ROM when including both cancer and noninvasive follicular thyroid neoplasia with papillary‐like features (cancer+NIFTP) and 68% malignant diagnosis when excluding NIFTP. RAS‐like alterations were most common (66%), exhibiting a 73.4% ROM and a 59% malignant diagnosis. Interestingly, this group included 24 encapsulated follicular variant papillary thyroid carcinomas (EFVPTCs), 1 infiltrative FVPTC, 9 follicular carcinomas, and 7 NIFTP. Additionally, three high‐risk mutations and eight BRAF/V600E mutations had a 100% ROM, all diagnosed as classic‐type papillary thyroid carcinoma (cPTC). Combined analysis of thyroid nodules from Bethesda III and IV categories revealed a 78.2% positive predictive value (PPV) and a 75.9% negative predictive value (NPV).Conclusion: ThyroSeq v3 effectively stratifies the ROM in indeterminate thyroid nodules based on specific genetic alterations, guiding appropriate surgical management. Notably, the BRAFV600E/high‐risk group and RAS‐like groups exhibited ROM of 100% and 77.5%, respectively, with promising predictive accuracy (PPV of 78.2% and NPV of 75.9%).


  • Comprehensive evaluation of cytomorphologic, histologic, and molecular features of DICER1‐altered thyroid lesions on FNA: A multipractice experience

    by Krisztina Lengyel, Daniel J. Lubin, Wen‐Yu Hsiao, Sam Sirotnikov, Guangju Luo, James W. Roberts, Qiuying Shi, Kelly Magliocca, Melinda M. Lewis, Donald L. Sears, et al.

    Background: DICER1 mutations, though infrequent, are encountered on preoperative molecular testing of indeterminate adult and pediatric thyroid fine‐needle aspiration (FNA) specimens. Yet, published cytomorphologic features of DICER1‐altered thyroid lesions are limited. Cytomorphological features of DICER1‐altered thyroid lesions were examined in a multipractice FNA cohort with clinical, radiological, and histologic data.Methods: The cohort comprised 18 DICER1‐altered thyroid FNAs, with 14 having slides available and eight having corresponding surgical resections. Smears, ThinPrep, and formalin‐fixed cell block slides were reviewed and correlated with histology, when available. Clinical and radiologic data were obtained from the medical record.Results: Most DICER1‐altered FNAs were classified as atypia of undetermined significance (94.4%). DICER1 mutations occurred in codons 1709 (50%), 1810 (27.8%), and 1813 (22.2%). One patient had an additional DICER1 p.D1822N variant in both of their FNAs. Lesions were often hypoechoic (35.3%) and solid (47.1%) on ultrasound. Notable cytomorphologic features include mixed but prominent microfollicular or crowded component, variable colloid, and insignificant nuclear atypia. On resection (n = 10), histologic diagnoses ranged from benign follicular adenoma and low‐risk follicular thyroid carcinoma to high‐grade follicular–derived nonanaplastic thyroid carcinoma. Subcapsular infarct‐type change was the most common histologic change. There was no evidence of recurrence or metastasis in eight patients on limited follow‐up.Conclusion: DICER1‐altered thyroid lesions occurred frequently in young females and FNAs show RAS‐like cytomorphology including crowded, mixed macro‐/microfollicular pattern, and bland nuclear features. On resection, DICER1‐altered thyroid lesions include benign (50%), low‐risk lesions (30%), or high‐risk malignancies (20%).


  • Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study

    by Bin Xu, Kartik Viswanathan, Mahsa S. Ahadi, Sara Ahmadi, Bayan Alzumaili, Mohamed-Amine Bani, Eric Baudin, David Blake Behrman, Marzia Capelletti, Nicole G. Chau, et al.

    Purpose: The prognostic importance of RET and RAS mutations and their relationship to clinicopathologic parameters and outcomes in medullary thyroid carcinoma (MTC) needs to be clarified. Experimental design: A multicenter retrospective cohort study was performed utilizing data from 290 patients with MTC. The molecular profile was determined and associations were examined with clinicopathologic data and outcomes. Results: RET germline mutations were detected in 40 patients (16.3%). Somatic RET and RAS mutations occurred in 135 (46.9%) and 57 (19.8%) patients respectively. RETM918T was the most common somatic RET mutation (n=75). RET somatic mutations were associated with male sex, larger tumor size, advanced AJCC stage, vascular invasion (VI), and high IMTCGS grade. When compared with other RET somatic mutations, RETM918T was associated with younger age, AJCC (8th edition) IV, vascular invasion, extrathyroidal extension, and positive margins. RET somatic or germline mutations were significantly associated with reduced distant metastasis free survival on univariate analysis but there were no significant independent associations on multivariable analysis, after adjusting for tumor grade and stage. There were no significant differences in outcomes between RET somatic and RET germline mutations, or between RETM918T and other RET mutations. Other recurrent molecular alterations included TP53 (4.2%), ARID2 (2.9%), SETD2 (2.9%), KMT2A (2.9%), and KMT2C (2.9%). Among them, TP53 mutations were associated with decreased overall and disease-specific survival, independently of tumor grade and AJCC stage. Conclusions: RET somatic mutations were associated with high-grade, aggressive primary tumor characteristics, and decreased distant metastatic-free survival but this relationship was not significant after accounting for tumor grade and disease stage . RETM918T was associated with aggressive primary tumors but was not independently associated with clinical outcomes. TP53 mutation may represent an adverse molecular event associated with decreased overall and disease-specific survival in MTC but its prognostic value needs to be confirmed in future studies.


  • Open Access

    Novel prognostic nomogram for predicting recurrence‐free survival in medullary thyroid carcinoma

    by Yagiz A Aksoy, Bin Xu, Kartik Viswanathan, Mahsa S Ahadi, Abir Al Ghuzlan, Bayan Alzumaili, Mohamed‐Amine Bani, Justine A Barletta, Nicole Chau, Angela Chou, et al.

    Aims: Recently, there have been attempts to improve prognostication and therefore better guide treatment for patients with medullary thyroid carcinoma (MTC). In 2022, the International MTC Grading System (IMTCGS) was developed and validated using a multi‐institutional cohort of 327 patients. The aim of the current study was to build upon the findings of the IMTCGS to develop and validate a prognostic nomogram to predict recurrence‐free survival (RFS) in MTC.Methods and Results: Data from 300 patients with MTC from five centres across the USA, Europe, and Australia were used to develop a prognostic nomogram that included the following variables: age, sex, AJCC stage, tumour size, mitotic count, necrosis, Ki67 index, lymphovascular invasion, microscopic extrathyroidal extension, and margin status. A process of 10‐fold cross‐validation was used to optimize the model's performance. To assess discrimination and calibration, the area‐under‐the‐curve (AUC) of a receiver operating characteristic (ROC) curve, concordance‐index (C‐index), and dissimilarity index (D‐index) were calculated. Finally, the model was externally validated using a separate cohort of 87 MTC patients. The model demonstrated very strong performance, with an AUC of 0.94, a C‐index of 0.876, and a D‐index of 19.06. When applied to the external validation cohort, the model had an AUC of 0.9.Conclusions: Using well‐established clinicopathological prognostic variables, we developed and externally validated a robust multivariate prediction model for RFS in patients with resected MTC. The model demonstrates excellent predictive capability and may help guide decisions on patient management. The nomogram is freely available online at https://nomograms.shinyapps.io/MTC_ML_DFS/.


  • Cytomorphologic Evaluation of DICER1-Altered Thyroid Neoplasms on Fine Needle Aspiration

    by Krisztina Lengyel, Wen-Yu Hsiao, Qiuying Shi, James Roberts, Melinda M. Lewis., J. Daniel, Kartik Viswanathan

  • Ki67 proliferation index in medullary thyroid carcinoma: a comparative study of multiple counting methods and validation of image analysis and deep learning platforms

    by Saad Nadeem, Matthew G Hanna, Kartik Viswanathan, Joseph Marino, Mahsa Ahadi, Bayan Alzumaili, Mohamed‐Amine Bani, Federico Chiarucci, Angela Chou, Antonio De Leo, et al.

    Aims: The International Medullary Thyroid Carcinoma Grading System, introduced in 2022, mandates evaluation of the Ki67 proliferation index to assign a histological grade for medullary thyroid carcinoma. However, manual counting remains a tedious and time‐consuming task.Methods and results: We aimed to evaluate the performance of three other counting techniques for the Ki67 index, eyeballing by a trained experienced investigator, a machine learning‐based deep learning algorithm (DeepLIIF) and an image analysis software with internal thresholding compared to the gold standard manual counting in a large cohort of 260 primarily resected medullary thyroid carcinoma. The Ki67 proliferation index generated by all three methods correlate near‐perfectly with the manual Ki67 index, with kappa values ranging from 0.884 to 0.979 and interclass correlation coefficients ranging from 0.969 to 0.983. Discrepant Ki67 results were only observed in cases with borderline manual Ki67 readings, ranging from 3 to 7%. Medullary thyroid carcinomas with a high Ki67 index (≥ 5%) determined using any of the four methods were associated with significantly decreased disease‐specific survival and distant metastasis‐free survival.Conclusions: We herein validate a machine learning‐based deep‐learning platform and an image analysis software with internal thresholding to generate accurate automatic Ki67 proliferation indices in medullary thyroid carcinoma. Manual Ki67 count remains useful when facing a tumour with a borderline Ki67 proliferation index of 3–7%. In daily practice, validation of alternative evaluation methods for the Ki67 index in MTC is required prior to implementation.


  • Non-Neoplastic

    by William C. Faquin, Massimo Bongiovanni, Fabiano Callegari, Tarik M. Elsheikh, Daniel F. I. Kurtycz, Oscar Lin, Ravi Mehrotra, Marc P. Pusztaszeri, Judy Qiuying Shi, Zhihui Zhang